Published in Cancer Discov on November 30, 2016
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell (2017) 0.94
What does PD-L1 positive or negative mean? J Exp Med (2016) 0.79
Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. Front Oncol (2017) 0.79
Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol (2017) 0.77
The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol (2017) 0.75
Immunotherapy resistance: the answers lie ahead - not in front - of us. J Immunother Cancer (2017) 0.75
Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the JAK2 gene in non-small cell lung cancer. Oncotarget (2017) 0.75
Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma. Front Immunol (2017) 0.75
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma Res (2017) 0.75
A novel combination strategy for effectively targeting cancer stem-like cells. Immunol Cell Biol (2017) 0.75
PD1 signal transduction pathways in T cells. Oncotarget (2017) 0.75
Molecular genetic and immunotherapeutic targets in metastatic melanoma. Virchows Arch (2017) 0.75
Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol (2017) 0.75
Transcriptional-mediated effects of radiation on the expression of immune susceptibility markers in melanoma. Radiother Oncol (2017) 0.75
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res (2012) 15.90
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 11.57
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
The future of immune checkpoint therapy. Science (2015) 5.59
The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature (1993) 5.24
The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol (1997) 4.76
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov (2013) 4.39
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med (2016) 4.33
Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature (1993) 4.20
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature (2015) 3.86
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (2016) 3.38
Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell (1998) 3.25
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell (2016) 2.65
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med (2016) 2.54
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA (2016) 2.41
Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res (2014) 2.27
Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann Oncol (2014) 2.08
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell (2016) 2.00
IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res (2005) 1.75
Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer (2014) 1.59
Oncotator: cancer variant annotation tool. Hum Mutat (2015) 1.52
Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discov (2015) 1.28
Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes. Mol Cancer Res (2014) 0.99
JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations. Sci Rep (2013) 0.99
Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNgamma-induced apoptosis. Gene Ther (2003) 0.88
COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Mol Oncol (2013) 0.87